ArticleFrontiers in immunology2026
Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of anti-drug antibodies (ADAs) in response to therapeutic monoclonal antibody (mAb) treatments can undermine their efficacy and safety. A key player in this immunogenicity is the presentation of mAb-derived peptides by dendritic cells, which activates CD4+ T-helper cells. Traditionally, the MHC class II-associated peptide proteomics (MAPPs) assay is used preclinically to identify these peptides presented by monocyte-derived dendritic cells (moDCs). Here, we are introducing "clinical MAPPs", an optimized, miniaturized version of the assay tailored for clinical use. Designed to work with cryopreserved peripheral blood mononuclear cells from low blood volumes (10 mL), clinical MAPPs offers a groundbreaking approach. Our proof-of-concept on patient material shows that clinical MAPPs enables personalized characterization of MHC-II receptor-associated antibody-derived peptides before mAb treatment. This innovative assay promises to be a critical tool for clinical immunogenicity risk assessments, enhancing personalized healthcare and ensuring safer, more effective treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.